Valuation: Wockhardt Limited

Market Cap 309B 3.25B 2.91B 2.68B 2.43B 4.54B 4.62B 31.96B 12.83B 162B 12.21B 11.95B 512B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 324B 3.42B 3.06B 2.81B 2.55B 4.77B 4.86B 33.57B 13.48B 171B 12.82B 12.55B 538B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.99%
Yield 2025 *
-
Yield 2026 -
1 day-1.13%
1 week+2.46%
Current month-10.17%
1 month-13.36%
3 months-0.80%
6 months+36.60%
Current year+31.45%
1 week 1,780.5
Extreme 1780.5
1,960.5
1 month 1,772
Extreme 1772
2,197
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 222.55
Extreme 222.55
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 31/03/2009
Director of Finance/CFO - 28/02/2022
Chief Tech/Sci/R&D Officer - 30/04/1998
Director TitleAgeSince
Chairman 83 05/11/2009
Director/Board Member 74 28/08/2020
Director/Board Member 53 05/11/2009
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%+2.46%+45.50%+750.03% 3.28B
+3.09%+10.92%+67.26%+149.68% 1,224B
-0.50%+3.81%+44.87%+86.27% 662B
+1.45%+2.84%+28.73%+107.04% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.33%+3.02%+73.45%+45.74% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+1.46%+6.28%+59.88%+77.38% 249B
+3.72%+9.84%+44.71%+120.39% 205B
Average +1.94%+2.70%+46.51%+149.84% 418.01B
Weighted average by Cap. +2.09%+3.04%+50.79%+98.52%

Financials

2025 2026
Net sales 30.35B 320M 286M 263M 239M 446M 454M 3.14B 1.26B 15.96B 1.2B 1.17B 50.35B 34.62B 365M 327M 300M 272M 509M 518M 3.58B 1.44B 18.21B 1.37B 1.34B 57.43B
Net income -470M -4.95M -4.43M -4.08M -3.69M -6.91M -7.04M -48.63M -19.52M -247M -18.58M -18.18M -780M 2.13B 22.43M 20.09M 18.48M 16.74M 31.3M 31.89M 220M 88.47M 1.12B 84.19M 82.4M 3.53B
Net Debt 14.33B 151M 135M 124M 113M 211M 215M 1.48B 595M 7.54B 566M 554M 23.77B 15.53B 164M 146M 135M 122M 228M 232M 1.61B 645M 8.17B 614M 601M 25.76B
Projected Income Statement - Annual - Wockhardt Limited
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
30/10/26 ₹1,901.10 -1.13% 506,696
29/10/26 ₹1,922.90 +0.50% 496,528
28/10/26 ₹1,913.40 +1.52% 490,596
27/10/26 ₹1,884.80 +4.16% 524,659
26/10/26 ₹1,809.60 +0.44% 798,653
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock